Cargando…
P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS
Autores principales: | Hueso, Thomas, Rahme, Ramy, Vidal, Valerie, Ivanoff, Sarah, Brechignac, Sabine, Lazarian, Gregory, Ghez, David, Roos-Weil, Damien, Baran-Marszak, Fanny, Gardin, Claude, Braun, Thorsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431286/ http://dx.doi.org/10.1097/01.HS9.0000970748.06478.55 |
Ejemplares similares
-
PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
por: Taleb, Assia, et al.
Publicado: (2023) -
Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
por: Bai, Xueyan, et al.
Publicado: (2015) -
Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
por: Xu, XiaoWei, et al.
Publicado: (2013) -
A case of acquired angioedema associated with Waldenstrom’s macroglobulinemia treated with rituximab
por: Rizk, Caroline, et al.
Publicado: (2014) -
Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab
por: Traboulsi, Danya, et al.
Publicado: (2018)